Updates

Craneware

September 2024

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

Ahead of reporting on 3 September, Craneware said it expects sales for FY24 to exceed US$188m (+8% year-on-year) and EBITDA of at least US$58m for a c.31% margin, beating consensus. The outperformance reflects both a strong sales performance and success in Craneware’s partner programmes. Partner revenues (those derived from Trisus-enabled third-party applications) increased from US$1.1m in H2 23 to US$5.6m in H1 24. Annual recurring revenue has now climbed to US$172m. Tipped at 1500p in October ‘23, the shares have already gained 53%. Strong hold for more/buy. ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

ME Group - Cavendish initiates with 350p price target

Mircrolise

Craneware - Growing pipeline of opportunities (October 2023)

Craneware (July 2019)

Craneware (August 2018)

Craneware - Two significant new contracts (March 2018)

Craneware - Gain since main profile: 154% (February 2018)

Craneware - Bullet proof business (October 2016)

Craneware (August 2016)

Craneware - Big beneficiary of Obamacare (November 2015)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X